Med·Investment | News: Medical Device Investment Events (2025.03.08–2025.03.21)

Singular Medical announced the completion of a nearly 150 million yuan Series C financing round. This round was led by Tasly Capital, with continued support from existing shareholders Qiming Venture Partners, SND Holdings, and Kangyu Capital. The funds raised will be used for the development and commercialization of the company’s next-generation products.

Singular Medical is a leader in the research, development, and production of Cardiac Rhythm Management (hereinafter referred to as "CRM") medical devices in China, committed to building a high-end CRM medical device brand in China. The company's product line covers Implantable Cardioverter Defibrillators (hereinafter referred to as "ICD"), Insertable Cardiac Monitors (hereinafter referred to as "ICM"), pacemakers, and more. By bringing together experts from both China and the United States, the company has, over the course of eight years, accumulated deep technical expertise and industry solution experience in this field, establishing core technological capabilities and implementation methodologies covering the entire lifecycle of CRM systems.

Singular Medical's Anbo® ICD began clinical trials at the end of 2023, completing all patient enrollment and follow-ups, and has successfully treated dozens of ventricular arrhythmia subjects outside the hospital. This product, with full independent intellectual property rights, matches the performance of mainstream imported products and demonstrates excellent clinical outcomes.

Singular Medical® ICM began clinical trials at the end of 2023. All participants have been enrolled and followed up, demonstrating excellent clinical performance with a leading advantage in precise P-wave visibility. The product is equipped with Bluetooth telemetry, supporting real-time cloud transmission via mobile phones, providing more timely diagnostic and therapeutic assistance functions, covering home monitoring.

ECLINCLOUD is an industry-leading AI technology company dedicated to reshaping the industry landscape through cutting-edge technology. The company's team consists of medical experts from internationally renowned enterprises such as Pfizer, Novo Nordisk, and IQVIA, as well as technical elites from tech giants like IBM and Oracle. The core team has over 15 years of experience in new drug development at internationally leading technology companies or innovative pharmaceutical enterprises. Additionally, ECLINCLOUD’s independently established AI Innovation Center brings together artificial intelligence experts and advisory teams within the industry, providing solid support for technological breakthroughs.

Since its establishment, ECLINCLOUD has always been committed to building its products and services according to international standards. Its self-developed SaaS cloud platform supports multi-language operations, is deployed on cloud servers in both China and the US, and allows for flexible selection of data storage locations based on project requirements, ensuring data security and compliance. This makes it perfectly adaptable to regulatory requirements across multiple regions including the US and the EU. This technical architecture has successfully supported numerous multinational, multi-center research projects, fully demonstrating its global competitiveness.

In the future, ECLINCLOUD will continue to expand its international talent team and deepen its global cooperation network, helping clients efficiently implement international strategies and further solidifying its core position in the field of global clinical research digitalization.

Prusun Shunxiang team has深耕in the medical device industry for many years. The founder, Zou Jianlong, once created Anhe Jiali'er, the leading domestically-produced ultrasonic knife brand in China, and successfully conducted its merger and sale. Based on years of technical accumulation and clinical achievement transformation, the company has built five core technology platforms: trauma surgery, energy surgery, electronic endoscopy, high-value consumables, and CDMO. It boasts a rich product portfolio, covering varieties such as ultrasonic aspiration knives, radiofrequency plasma, ultrasonic knife systems, urological surgical series consumables, endoscopic surgical systems, and nerve conduit tubes. The company has obtained more than 30 medical device registrations both domestically and internationally.

As the first year of commercialization in 2024, several innovative products have entered clinical use in multiple top-tier tertiary hospitals in China, receiving unanimous praise from clinical experts.

The company has always been guided by clinical needs, adhering to technological innovation. Its product iterations closely follow the pace of medical advancements, achieving significant results in addressing clinical issues. It not only provides stable and reliable products for established surgical procedures but also develops original instruments for advanced techniques. Its technical capabilities and product quality have earned recognition from industry giants.

Fire Eyes Crystal was established in 2022, dedicated to building a digital optometry platform using XR+AI technology with the aim of addressing the imbalance in medical resources and bringing benefits to more patients with eye health issues. Its current products include the Fire Eyes Crystal M1 VR Intelligent Vision Training Device for teenagers and children, an adult vision fatigue and presbyopia intelligent vision training device, and the Shilang Qing VR Low Vision Intelligent Visual Aid.

The core product of the company, the Fire Eye Crystal VR Intelligent Vision Training Instrument M1 for teenagers and children, is an intelligent visual health solution jointly developed by Fire Eye Crystal and Zhongshan Ophthalmology. Relying on an integrated technology platform of "optics, mechanics, electronics, software, and computing," it provides myopia prevention, myopia control, and visual function examination services for children and adolescents aged 6-12.

This product adopts the globally leading Pancake short-focus optical technology, creating the thinnest and lightest near-eye ultra-distance product in the industry (with a total weight of only 160 grams). It is comfortable and lightweight to wear, meeting national visual health and safety standards as well as TÜV anti-blue light certification, ensuring the safety of non-invasive training. Additionally, the product can design differentiated training programs based on the visual developmental characteristics of children at different ages and individual visual function parameters. The accompanying optometry cloud system establishes exclusive vision archives for children, recording professional optometric data such as diopter, axial length, PRA/NRA, and generates personalized training plans through cloud-based big data analysis, achieving precise myopia prevention and control solutions that meet clinical standards. From the successful launch of the healthcare-grade products Huo Yan Jing Jing E1 and E1Pro to the medical-grade product M1, the company has consistently upheld an innovative spirit, driving continuous iteration and upgrades of its products.

Kunshi Biotech, established in 2021, is a clinical-stage company focused on the research and development of macrophage-based drugs for cancer and chronic diseases. It is also the world’s only company with a technology platform that integrates live cell factors in series and features gene editing, biomaterials, and synthetic biology-driven engineered macrophage technologies. The company has been honored with several prestigious awards, including National High-tech Enterprise, Major Leading Talent in Suzhou Industrial Park's Science and Technology Leadership Program, Science and Technology SME, Innovative SME, and Jiangsu Province Private Science and Technology Enterprise, while also undertaking national-level "Challenge Leader" technical research projects.

Since its establishment, Kunshi Bio has focused on the development and clinical application of macrophage-based drugs for treating tumors and chronic diseases, actively promoting the research and industrialization of Chimeric Antigen Receptor Macrophages (CAR-M). A preparation room meeting GMP standards with cleanliness lab specifications (B+A) has been established in Suzhou Industrial Park, and the company is advancing nine CAR-M cell drug pipelines through multi-center collaborations with multiple institutions worldwide.